MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) was upgraded by investment analysts at RODMAN&RENSHAW to a “strong-buy” rating in a research note issued to investors on Monday, Zacks.com reports.
MIRA has been the topic of several other research reports. Ascendiant Capital Markets initiated coverage on MIRA Pharmaceuticals in a research note on Monday, August 5th. They set a “buy” rating and a $11.00 target price on the stock. Rodman & Renshaw started coverage on shares of MIRA Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $17.00 price objective on the stock.
Check Out Our Latest Stock Analysis on MIRA
MIRA Pharmaceuticals Stock Performance
MIRA Pharmaceuticals (NASDAQ:MIRA – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). On average, research analysts forecast that MIRA Pharmaceuticals will post -0.6 EPS for the current fiscal year.
Institutional Trading of MIRA Pharmaceuticals
A number of institutional investors have recently bought and sold shares of the company. Praetorian Wealth Management Inc. acquired a new position in MIRA Pharmaceuticals in the 1st quarter worth about $30,000. Suncoast Equity Management bought a new stake in shares of MIRA Pharmaceuticals in the 1st quarter valued at approximately $44,000. Virtu Financial LLC increased its holdings in MIRA Pharmaceuticals by 330.2% in the first quarter. Virtu Financial LLC now owns 63,055 shares of the company’s stock worth $69,000 after buying an additional 48,397 shares during the last quarter. Finally, Cross Staff Investments Inc bought a new position in MIRA Pharmaceuticals during the first quarter valued at approximately $422,000. Institutional investors and hedge funds own 35.16% of the company’s stock.
About MIRA Pharmaceuticals
MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.
Further Reading
- Five stocks we like better than MIRA Pharmaceuticals
- What is an Earnings Surprise?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- 3 Healthcare Dividend Stocks to Buy
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Ride Out The Recession With These Dividend KingsĀ
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for MIRA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MIRA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.